Targeting interleukin-2 as a treatment for psoriasis.
Interleukin (IL)-2 is known to play a key role in the pathophysiology of psoriasis by activating T-cells. In recent years, therapies have been developed to specifically prevent T-cell activation by blocking the production of IL-2 or by inhibiting its action. These new therapies are discussed.
Salim
A
A
Department of Dermatology, North Staffordshire Hospital, Stoke-on Trent, UK. salim@doctors.org.uk
Emerson
R
R
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015375:Receptors, Interleukin-2